Immune–inflammatory response after bioresorbable vascular scaffold implantation in patients with acute myocardial infarction with ST elevation in a long-term perspective

  • Martin Kozel
  • Viktor Kočka
  • Libor Lisa
  • Tomáš Buděšínský
  • Petr ToušekEmail author
Original Article


A higher rate of bioresorbable vascular scaffold (BVS) thrombosis has been observed after device implantation compared to implantation of permanent metallic stents in recently published studies. The mechanism of BVS thrombosis is currently under debate. To assess whether the immune–inflammatory response after BVS implantation is a potential trigger of BVS thrombosis. The PRAGUE-19 study was an academic study that enrolled consecutive patients with ST-segment elevation myocardial infarction (STEMI) with the intention to implant a BVS. A laboratory sub-study included 49 patients with an implanted BVS (of which 38 underwent the complete 2-year follow-up) and 52 patients having an implanted permanent metallic stent as the control group (of which 30 underwent the complete 2-year follow-up). Samples for inflammatory markers [high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α)] were taken before BVS or stent implantation, on days 1 and 2 after device implantation and at 1 month and 2 years for a clinical control. The primary combined clinical endpoint of the sub-study (death, reinfarction or target vessel revascularization) occurred in 4.08% of the BVS group and 7.69% of the control group (p = 0.442) during the 2-year follow-up period, with overall mortality of 2.04% in the BVS group and 1.92% in the control group (p = 0.966). Definite BVS thrombosis occurred in one patient in the subacute phase; there was no late or very late thrombosis. Two definite stent thromboses were observed in the control group: one in the subacute phase and the other in the late phase. Baseline inflammatory marker levels did not differ between the groups. Lower levels of IL-6 and hs-CRP were observed in the BVS group compared to the control group (12.02 ± 5.94 vs. 15.21 ± 5.33 pg/ml; p < 0.01; 3952.9 ± 1704.75 ng/ml vs. 4507.49 ± 1190.01 ng/ml; p = 0.037, respectively) on days 1 and 2 (12.01 ± 6.31 vs. 13.85 ± 6.01 pg/ml; p = 0.089; 4447.92 ± 1325.31 ng/ml vs. 4637.03 ± 1290.99 ng/ml; p = 0.255, respectively). No differences in IL-6 or hs-CRP were observed after 1 month or 2 years in the clinical control. Levels of TNF-α did not differ between the groups in the early period after BVS or metallic stent implantation, nor during follow-up. The immune–inflammatory response is lower during the early phase after BVS implantation compared to that after metallic stent implantation, but the responses did not differ in the long term.


Bioresorbable vascular scaffold Percutaneous coronary intervention Myocardial infarction Thrombosis Immune–inflammatory reaction 



This study was supported by Charles University Research Program Q38 and Charles University Research Centre Programme UNCE/MED/002.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Kang SH, Chae IH, Park JJ, Lee HS, Kang DY, Hwang SS, Youn TJ, Kim HS (2016) Stent thrombosis with drug-eluting stents and bioresorbable scaffolds: evidence from a network meta-analysis of 147 trials. JACC Cardiovasc Interv 9:1203–1212CrossRefGoogle Scholar
  2. 2.
    Lipinski MJ, Escarcega RO, Baker NC, Benn HA, Gaglia MA Jr, Torguson R, Waksman R (2016) Scaffold thrombosis after percutaneous coronary intervention with ABSORB bioresorbable vascular scaffold: a systematic review and meta-analysis. JACC Cardiovasc Interv 9:12–24CrossRefGoogle Scholar
  3. 3.
    Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R (2007) Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 27:1500–1510CrossRefGoogle Scholar
  4. 4.
    Kočka V, Malý M, Toušek P, Buděšínský T, Lisa L, Prodanov P, Jarkovský J, Widimský P (2014) Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study ‘Prague 19’. Eur Heart J 35:787–794CrossRefGoogle Scholar
  5. 5.
    Stone GW, Gao R, Kimura T, Kereiakes DJ, Ellis SG, Onuma Y, Cheong WF, Jones-McMeans J, Su X, Zhang Z, Serruys PW (2016) 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet 387(10025):1277–1289CrossRefGoogle Scholar
  6. 6.
    Sabaté M, Brugaletta S, Cequier A (2014) The EXAMINATION trial: 2-year results from a multicenter randomized controlled trial. JACC Cardiovasc Interv 7:64–71CrossRefGoogle Scholar
  7. 7.
    Kimura T, Morimoto T, Kozuma K, Honda Y, Kume T, Aizawa T, Mitsudo K, Miyazaki S, Yamaguchi T, Hiyoshi E, Nishimura E, Isshiki T, RESTART Investigators (2010) Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). Circulation 122:52–61CrossRefGoogle Scholar
  8. 8.
    Toušek P, Kočka V, Malý M, Lisa L, Buděšínský T, Widimský P (2016) Neointimal coverage and late apposition of everolimus-eluting bioresorbable scaffolds implanted in the acute phase of myocardial infarction: OCT data from the PRAGUE-19 study. Heart Vessels 31(6):841–845CrossRefGoogle Scholar
  9. 9.
    Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293:2126–2130CrossRefGoogle Scholar
  10. 10.
    Camenzind E, Steg PG, Wijns W (2007) Stent thrombosis late after implantation of first generation drug-eluting stents: a cause for concern. Circulation 115:1440–1455 (discussion 1455) CrossRefGoogle Scholar
  11. 11.
    Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabate M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schomig A (2007) Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356:1030–1039CrossRefGoogle Scholar
  12. 12.
    Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB (2007) Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356:998–1008CrossRefGoogle Scholar
  13. 13.
    Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P (2007) Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370:937–948CrossRefGoogle Scholar
  14. 14.
    Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369:667–678CrossRefGoogle Scholar
  15. 15.
    Byrne RA, Iijima R, Mehilli J, Pinieck S, Bruskina O, Schomig A, Kastrati A (2009) Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv 2:291–299CrossRefGoogle Scholar
  16. 16.
    Togni M, Raber L, Cocchia R, Wenaweser P, Cook S, Windecker S, Meier B, Hess OM (2007) Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. Int J Cardiol 120:212–220CrossRefGoogle Scholar
  17. 17.
    Otsuka F, Byrne RA, Yahagi K, Mori H, Ladich E, Fowler DR, Kutys R, Xhepa E, Kastrati A, Virmani R, Joner M (2015) Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J 36:2147–2159CrossRefGoogle Scholar
  18. 18.
    Tada T, Byrne RA, Simunovic I, King LA, Cassese S, Joner M, Fusaro M, Schneider S, Schulz S, Ibrahim T, Ott I, Massberg S, Laugwitz KL, Kastrati A (2013) Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv 6:1267–1274CrossRefGoogle Scholar
  19. 19.
    Raber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y, Wenaweser P, Daemen J, Meier B, Juni P, Serruys PW, Windecker S (2012) Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 125:1110–1121CrossRefGoogle Scholar
  20. 20.
    Chen Y, Zhang Q, Liao YH (2011) Effect of tumor necrosis factor-alpha on neutralization of ventricular fibrillation in rats with acute myocardial infarction. Mediat Inflamm. 2011:565238CrossRefGoogle Scholar
  21. 21.
    Deliargyris EN, Raymond RJ, Theoharides TC, Boucher WS, Tate DA, Dehmer GJ (2000) Sites of interleukin-6 release in patients with acute coronary syndromes and in patients with congestive heart failure. Am J Cardiol 86:913–918CrossRefGoogle Scholar
  22. 22.
    Mendall MA, Patel P, Ballam L, Strachan D, Morthfield TC (1996) C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 312(7038):1061–1065CrossRefGoogle Scholar
  23. 23.
    Morrow DA, Rifai N, Antman EM, Weiner DL, Mccabe CH, Canno CP, Braunwald E (1998) C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes. J Am Coll Cardiol 31:1460–1465CrossRefGoogle Scholar
  24. 24.
    Pietila K, Harmoinen A, Hermens W, Simoons ML, Van de Werf F, Verstraete M (1993) Serum C-reactive protein and infarct size in myocardial infarct in patients with a closed versus an open infarct-related coronary artery after thrombolytic therapy. Eur Heart J 14(7):915–919CrossRefGoogle Scholar
  25. 25.
    Pietila K, Harmoinen AP, Jokinitty J, Pasternack AI (1996) Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J 17:1345–1349CrossRefGoogle Scholar
  26. 26.
    Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448–454CrossRefGoogle Scholar
  27. 27.
    Ikeda U, Ito T, Shimada K (2001) Interleukin-6 and acute coronary syndrome. Clin Cardiol 24:701–704CrossRefGoogle Scholar
  28. 28.
    Kefer JM, Galanti LM, Desmet S, Deneys V, Hanet CE (2005) Time course of release of inflammatory markers after coronary stenting: comparison between bare metal stent and sirolimus-eluting stent. Coron Artery Dis 16(8):505–559CrossRefGoogle Scholar
  29. 29.
    Chen SL, Liu Y, Lin L, Ye F, Zhang JJ, Tian NL, Zhang JX, Hu ZY, Xu T, Li L, Xu B, Latif F, Nguyen T (2014) Interleukin-6, but not C-reactive protein, predicts the occurrence of cardiovascular events after drug-eluting stent for unstable angina. J Interv Cardiol 27(2):142–154CrossRefGoogle Scholar

Copyright information

© Springer Japan KK, part of Springer Nature 2018

Authors and Affiliations

  • Martin Kozel
    • 1
  • Viktor Kočka
    • 1
  • Libor Lisa
    • 1
  • Tomáš Buděšínský
    • 1
  • Petr Toušek
    • 1
    Email author
  1. 1.Cardiocenter, Third Faculty of MedicineCharles University and University Hospital Královské VinohradyPrague 10Czech Republic

Personalised recommendations